You just read:

Daratumumab (DARZALEX®) Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Use in Combination with Standard of Care Regimens for Patients with Multiple Myeloma

News provided by

Janssen Research & Development, LLC

25 Jul, 2016, 20:56 ET